Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00477893
Status:
UNKNOWN
Last Update Posted:
2012-03-28
First Post:
2007-05-23
Brief Title:
Danish Multicenter Study of Adalimumab in Spondyloarthritis
Sponsor:
Glostrup University Hospital Copenhagen
Organization:
Glostrup University Hospital Copenhagen
Study Overview
Official Title:
Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab
Status:
UNKNOWN
Status Verified Date:
2012-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DANISH
Brief Summary:
Spondyloarthropathies SpA are often diagnosed with a considerable delay often 8-10 years from symptom onset because the available clinical biochemical and radiological methods are not sufficiently sensitive TNF-a antagonists have recently been introduced for treatment of SpA and current data indicate a higher efficacy than previously available therapies The improved treatment options have increased the need for improved methods for diagnosis monitoring and prognostication of these diseases so that the efficient therapies can be initiated at the optimal time point and monitored optimally Magnetic resonance imaging MRI and a number of biomarkers are promising but not yet sufficiently studied methods for this
Detailed Description:
See brief summary
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None